Voxelotor
- Generic Name
- Voxelotor
- Brand Names
- Oxbryta
- Drug Type
- Small Molecule
- Chemical Formula
- C19H19N3O3
- CAS Number
- 1446321-46-5
- Unique Ingredient Identifier
- 3ZO554A4Q8
- Background
Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications arising from the blockage of blood vessels....
- Indication
In the US, voxelotor is indicated to treat sickle cell disease in both adult and pediatric patients aged 4 years and older. In Europe, it is indicated for the treatment of hemolytic anemia due to sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older as monotherapy or in combination with hydroxyurea.
- Associated Conditions
- Hemolytic Anemia, Sickle Cell Disease (SCD)
- Associated Therapies
- -
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.